secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009642
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026
--------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.
- Canvuparatide (HP): 1-year follow-up data from Phase 2 in Q2 2026; Phase 3 start on track for Q3 2026.
- MBX 4291 (obesity, GLP-1/GIP prodrug): 12-week Phase 1 data expected Q4 2026; potential once-monthly dosing.
- Two additional obesity candidates to be nominated in Q2 and Q3 2026: amycretin prodrug and GLP-1/GIP/GCGR triple agonist.
- Imapextide (PBH): Phase 2a data in Q2 2026; once-weekly dosing preferred in patient surveys.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526009642/0001193125-26-009642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526009642/mbx-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer